Association between Visual Evoked Potential and Disease Severity, Disease Duration and Visual Hallucination in Patients with Idiopathic Parkinsonism
Background: Parkinson's disease (PD) is a neurodegenerative disorder impairing motor, verbal and other abilities. Visual evoked potential (VEP) assessment is a useful method for analysis of visual system and its function. The present study was designed in order to evaluate whether VEP changes are associated with PD.
Materials and Methods: In the present study, 100 subjects encompassing 40 patients with Idiopathic Parkinson’s Disease (Idiopathic PD) and 60 aged-matched controls were selected and assigned into case and control groups, respectively. VEP analysis was conducted in either group and the results were compared.
Results: In the present study, 16 patients (40%) showed prolonged P100 latency. P100 latency in the case group was significantly longer than in controls. P100 Amplitude was significantly higher in case group than control. There were no significant association between prolonged VEP and sex and diseases duration, in the participants. Also from our participants who suffer from visual hallucination, P100 latency was significantly longer than in the controls. There was a significant association between prolonged P100 latency and severity of disease in the case group.
Conclusion: We suggest that prolonged VEP latencies and amplitude are associated with PD and might be associated with a predisposition for visual hallucinations.
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-34.
Perfetti B, Moisello C, Lanzafame S, Varanese S, Landsness E, Onofrj M, Di Rocco A, Tononi G, Ghilardi MF. Attention modulation regulates both motor and non-motor performance: a high-density EEG study in Parkinson's disease. Archives italiennes de biologie. 2010;148(3):279-88.
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.
Andalib S, Vafaee MS, Gjedde A. Parkinson's disease and mitochondrial gene variations: A review. J Neurol Sci. 2014. DOI: 10.1016/j.jns.2014.07.067 (In Press)
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76.
Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744-54.
Farhoudi M, Sadigh-Eteghad S, Andalib S, Vafaee MS, Ziaee M, Mahmoudi J. An analytical review on probable anti-parkinsonian effect of modafinil. J Analyt Res Clin Med. 2013;1(2):58-62.
Armstrong RA. Visual symptoms in Parkinson's disease. Parkinsons Dis. 2011;2011:908306.
Bandini F, Pierantozzi M, Bodis-Wollner I. Parkinson's disease changes the balance of onset and offset visual responses: an evoked potential study. Clin Neurophysiol. 2001;112(6):976-983.
Antal A, Terney D, Bodis-Wollner I. Parkinson's disease, aging, and visual cognition. Topics in Geriatric Rehabilitation. 2008;24(2):166-81.
Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson's disease: clues to separate origins. Journal of the neurological sciences. 2006;248(1):143-150.
Okuda B, Tachibana H, Kawabata K, Takeda M, Sugita M. Visual evoked potentials (VEPs) in Parkinson's disease: correlation of pattern VEPs abnormality with dementia. Alzheimer Dis Assoc Disord. 1995;9(2):68-72.
Gottlob I, Schneider E, Heider W, Skrandies W. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalogr Clin Neurophysiol. 1987;66(4):349-357.
Yazdchi M, Talebi M, Aghbiglo AM, Mashrabi O. Role of visual evoked potential (VEP) and Somatosensory evoked potential (SSEP) in prediction Parkinson's diseases with dementia. Int J Curr Res Aca Rev.2(7):177-86.
Gawel MJ, Das P, Vincent S, Rose FC. Visual and auditory evoked responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1981;44(3):227-32.
Klistorner A, Garrick R, Barnett MH, Graham SL, Arvind H, Sriram P, Yiannikas C. Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology. 2012;80(3):242-5.
Talebi M, Sayadnasiri M, Azar SA. Effect of renal transplantation on visual evoked potential abnormalities of chronic renal failure. Transplant Proc. 2010;42(10):3994-7.
Azar SA, Talebi M, Aghdam AT, Shishavan RH, Andalib S. Comparison of Visual Evoked Potentials in Patients Undergoing Peritoneal Dialysis and Hemodialysis and its Association with Blood Biochemical Profile. J Expand Clin Neuro. 2014;1(1). DOI: http://dx.doi.org/10.13183/jecns.v1i1.4 (In Press)
Karlica D, Galetovic D, Ivanisevic M, Skrabic V, Znaor L, Jurisic D. Visual evoked potential can be used to detect a prediabetic form of diabetic retinopathy in patients with diabetes mellitus type I. Coll Antropol. 2010;34(2):525-9.
Sener HO, Akbostanci MC, Yucesan C, Dora B, Selcuki D. Visual evoked potentials in Parkinson's disease-correlation with clinical involvement. Clin Neurol Neurosurg. 2001;103(3):147-50.
Calzetti S, Franchi A, Taratufolo G, Groppi E. Simultaneous VEP and PERG investigations in early Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 1990;53(2):114-7.
Tartaglione A, Pizio N, Bino G, Spadavecchia L, Favale E. VEP changes in Parkinson's disease are stimulus dependent. Journal of Neurology, Neurosurgery & Psychiatry. 1984;47(3):305-7.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Archives of neurology. 1999;56(1):33-9.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology. 2001;57(10 Suppl 3):S11-26.
Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-7.
Kurita A, Murakami M, Takagi S, Matsushima M, Suzuki M. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Movement Disorders. 2010;25(2):167-71.
Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M. The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol. 2005;28(2):79-82.
Onofrj M, Thomas A, D'Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, Di Mascio R, Ballone E, Di Iorio A. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci. 2002;23 Suppl 2:S91-4.
Kupersmith MJ, Shakin E, Siegel IM, Lieberman A. Visual system abnormalities in patients with Parkinson's disease. Arch Neurol. 1982;39(5):284-6.